Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07028541

RemeOs™ DrillPin for Fixation of Distal Radius Fractures in Children

This is a pre-market, single-arm, open-label, monocenter clinical investigation evaluating the safety and performance of the magnesium (Mg)-based bioresorbable RemeOs™ DrillPin for surgical fixation of distal radius fractures in pediatric patients. The study will enroll 20 children aged over 5 and under 14 years to assess implantation success, early safety outcomes, and long-term effects on growth and bone healing.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Fracture Fixation, Internal Arm Injuries Distal Radius Fracture Fractures, Bone Wounds and Injuries Wrist Fractures Wrist Injuries

Age range

5 year–13 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This single-arm, open-label, monocenter clinical investigation is conducted in accordance with ISO 14155 to evaluate the safety and performance of the RemeOs™ DrillPin (a bioresorbable magnesium-based implant) used for internal fixation of distal radius fractures in pediatric patients.

Eligible participants are children aged over 5 and under 14 years who require surgical fixation of a distal radius fracture. The RemeOs™ DrillPin is designed to offer stable fracture fixation while gradually resorbing in the body, potentially reducing the need for implant removal.

Primary objectives include evaluating implantation success-defined by low pain levels (FACES® Pain Rating Scale score <3) and radiographic fracture healing in at least three cortices out of four across two imaging planes at 12 weeks postoperatively-and assessing short-term safety by monitoring adverse events, including device-related and serious adverse events.

Secondary assessments focus on postoperative clinical function and wrist range of motion (ROM), measured using a goniometer, as well as radiographic markers of implant biodegradation. Long-term safety is evaluated through the monitoring of potential growth disturbances at 52 and 104 weeks, including limb length discrepancies or growth plate abnormalities.

This early-stage investigation aims to generate clinical data on the application of magnesium-based resorbable implants in pediatric fracture care and to assess their potential to support bone healing without interfering with skeletal development.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Distal Radius Fractures
  • Written informed consent of the parent, oral agreement of the patient documented as informant consent of the child
  • Subject and parents have been informed of the nature of the study, agrees to participate and parent signs the approved consent form. • Female patients in childbearing age (female patients who have begun menstruation) perform a pregnancy test prior inclusion

Exclusion criteria

  • Pathological bone lesions (e.g. bone cyst or osteomyelitis)
  • Underlying diseases (kidney diseases, uncontrolled diabetes mellitus)
  • Polytraumatized patients
  • Suspicion of child abuse
  • Inability or unwillingness to give informed consent
  • Multiple fracture (excluding associated ulna fracture)
  • Open Fracture
  • Pregnancy (tested in all female patients who have begun menstruation)

Treatment and study plan

Magnesium-based bioresorbable DrillPin for fixation of distal radius fractures in children

Device

This is a first-in-child clinical investigation of a bioresorbable magnesium alloy DrillPin (RemeOs™) for fixation of distal radius fractures in children aged 5 to <14 years. The implant is investigational, not CE-marked or FDA-approved, and represents a novel alternative to traditional metallic implants. It gradually degrades in vivo, eliminating the need for removal. The study focuses on safety and feasibility in a pediatric population, supported by preclinical data from a similar Mg-based RemeOs™ Screw. The DrillPin's material and design are intended to support bone healing without growth disturbances, offering a state-of-the-art, bioresorbable solution tailored for growing patients.

Primary outcomes

  1. Number of participants with pain score <3 on the FACES® Pain Rating Scale (criterion of successful implantation)

    Time frame: At 12 weeks postoperatively

    This outcome is one of two predefined criteria used to determine successful implantation. Pain will be measured using the FACES® Pain Rating Scale. A score of less than 3 at 12 weeks postoperatively is considered a successful pain outcome. The FACES® Pain Rating Scale ranges from 0 (no pain) to 10 (worst pain).

  2. Number of participants with radiographic healing in at least 3 of 4 cortices on two-plane radiographs (criterion of successful implantation)

    Time frame: At 12 weeks postoperatively

    This outcome is one of two predefined criteria used to determine successful implantation. Radiographic healing will be assessed at 12 weeks postoperatively using standard anteroposterior and lateral radiographs. Healing is defined as the presence of visible callus formation in at least 3 of the 4 cortices (outer bone surfaces visible on two-plane imaging). Callus formation indicates new bone growth bridging the fracture site, and ≥3 healed cortices reflects adequate fracture consolidation.

  3. Number of participants with at least one adverse event (AE), adverse device effect (ADE), serious adverse event (SAE), or serious adverse device effect (SADE)

    Time frame: From day of surgery through 12 weeks postoperatively

    Safety will be assessed by documenting the occurrence, type, severity, and investigator-assessed relationship to the investigational device or implantation procedure for all adverse events. Events include adverse events (AEs), adverse device effects (ADEs), serious adverse events (SAEs), and serious adverse device effects (SADEs). The assessment will cover the period from surgery through 12 weeks postoperatively and will be based on clinical observations, subject reports, and medical record review.

Secondary outcomes

  1. Passive wrist range of motion (ROM) in degrees measured to assess functional recovery

    Time frame: 2, 4, 6 (optional), 12, 26, 52, and 104 weeks postoperatively

    Passive wrist range of motion (ROM) will be measured in degrees (°) using a goniometer at 2, 4, 6 (optional), 12, 26, 52, and 104 weeks postoperatively. The following directions of movement will be assessed independently: Extension/Flexion, Abduction/Adduction, Pronation/Supination.

    Measurements are recorded separately for the affected wrist and the contralateral (uninjured) wrist. Each direction will be expressed in degrees, and data will be used to evaluate functional recovery of wrist mobility over time.

  2. Number of participants with radiographic evidence of growth disturbance (growth arrest or length discrepancy)

    Time frame: At 52 and/or 104 weeks postoperatively

    Radiographic evaluation for growth disturbance will be performed at 52 and/or 104 weeks postoperatively if clinical assessment suggests axis deviation or deformity. A participant will be recorded as having a growth disturbance if either of the following is observed: Growth arrest or length discrepancy .

    This outcome will be reported as a binary (Yes/No) result per participant.

Study contacts

Contact information is provided by the study sponsor or research team.

Dr Clemens Seidl

CONTACT

[email protected]

+432236 9004

Prof. Dr. Dr. Thomas Klestil

CONTACT

[email protected]

+43 2236 9004 13201

Sponsors and collaborators

Lead sponsor

Bioretec Ltd.

Industry

Registry information

Official study title

To Evaluate the Feasibility of the Clinical Application of Mg-based RemeOs™ DrillPin for Fixation of Fractures of the Distal Radius in Children From the Age of Over 5 and Under 14.

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 19, 2025
Registry last updated
Jun 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.